People · Operator
Named in public records as an officer, director or promoter · active 2021–2025 · Biotechnology, Other, Healthtech, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Glympse Bio, Inc. | — | Biotechnology | Series C | $114.0M | $325.1M | 2023 |
| Auron Therapeutics, Inc. | — | Biotechnology | Series B | $81.8M | $159.4M | 2022 |
| Crossbow Therapeutics, Inc. | — | Biotechnology | Series B | $67.8M | $128.2M | 2023 |
| Podimetrics, Inc. | — | Other | Series C | $55.3M | $579.2M | 2021 |
| TRex Holdings Inc. | — | Biotechnology | Series C | $42.3M | $329.7M | 2024 |
| EpiBiologics, Inc. | — | Biotechnology | Series B | $30.0M | $570.2M | 2022 |
| BeMe Health, Inc. | — | Healthtech | Series A | $13.4M | $56.9M | 2022 |
| Cirrus Therapeutics, Inc. | — | Pharma | Series A | $6.7M | $21.1M | 2025 |
Alexandra Cantley at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alexandra Cantley on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 1 | 36 |
| Michael Ross | 1 | 18 |
| Carter Meyer | 1 | 14 |
| Todd Foley | 1 | 12 |
| Amy Schulman | 1 | 11 |
| Joel Marcus | 1 | 9 |
| George Zachary | 1 | 9 |
| Theresia Gouw | 1 | 8 |
| Briggs Morrison | 1 | 8 |
| Stanley Lapidus | 1 | 7 |
| Aaron Sandoski | 1 | 7 |
| Peter Hirth | 1 | 7 |
| Alon Lazarus | 1 | 7 |
| Sakae Asanuma | 1 | 6 |
| Carol Gallagher | 1 | 6 |
| Isaac Ciechanover | 1 | 5 |
| Andrew ` Offer | 1 | 5 |
| John McDonough | 1 | 5 |
| Mitchell Mutz | 1 | 5 |
| James Wells | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.